@5cata and Mozzarc - Thank you very much. I guess if/when it is approved and starts to earn a lot of money, big pharma will throw everything into trying to replicate it, but holders of Paradigm will have been rewarded by a tremendous increase in share price by then.
The novel drug - A DMOAD approach, page-22
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $78.73M | |||
| Open | High | Low | Value | Volume |
| 23.0¢ | 23.0¢ | 21.5¢ | $78.13K | 350.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 64880 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.5¢ | 43479 | 1 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |